Research ArticleClinical Investigations
Functional Imaging of Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Using 64Cu-DOTA-Trastuzumab PET
Joanne E. Mortimer, James R. Bading, David M. Colcher, Peter S. Conti, Paul H. Frankel, Mary I. Carroll, Shan Tong, Erasmus Poku, Joshua K. Miles, John E. Shively and Andrew A. Raubitschek
Journal of Nuclear Medicine January 2014, 55 (1) 23-29; DOI: https://doi.org/10.2967/jnumed.113.122630
Joanne E. Mortimer
1Department of Medical Oncology and Experimental Therapeutics, City of Hope, Duarte, California
James R. Bading
2Department of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute of the City of Hope, Duarte, California
David M. Colcher
2Department of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute of the City of Hope, Duarte, California
Peter S. Conti
3Molecular Imaging Center, Department of Radiology, University of Southern California, Los Angeles, California
Paul H. Frankel
4Department of Information Sciences, City of Hope, Duarte, California; and
Mary I. Carroll
1Department of Medical Oncology and Experimental Therapeutics, City of Hope, Duarte, California
Shan Tong
2Department of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute of the City of Hope, Duarte, California
Erasmus Poku
2Department of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute of the City of Hope, Duarte, California
Joshua K. Miles
2Department of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute of the City of Hope, Duarte, California
John E. Shively
5Department of Immunology, Beckman Research Institute of the City of Hope, Duarte, California
Andrew A. Raubitschek
2Department of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute of the City of Hope, Duarte, California
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 55, Issue 1
January 1, 2014
Functional Imaging of Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Using 64Cu-DOTA-Trastuzumab PET
Joanne E. Mortimer, James R. Bading, David M. Colcher, Peter S. Conti, Paul H. Frankel, Mary I. Carroll, Shan Tong, Erasmus Poku, Joshua K. Miles, John E. Shively, Andrew A. Raubitschek
Journal of Nuclear Medicine Jan 2014, 55 (1) 23-29; DOI: 10.2967/jnumed.113.122630
Functional Imaging of Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Using 64Cu-DOTA-Trastuzumab PET
Joanne E. Mortimer, James R. Bading, David M. Colcher, Peter S. Conti, Paul H. Frankel, Mary I. Carroll, Shan Tong, Erasmus Poku, Joshua K. Miles, John E. Shively, Andrew A. Raubitschek
Journal of Nuclear Medicine Jan 2014, 55 (1) 23-29; DOI: 10.2967/jnumed.113.122630
Jump to section
Related Articles
Cited By...
- Use of 64Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine for Metastatic Breast Cancer: A Pilot Study
- Phase I Study of 99mTc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer
- Towards integration of 64Cu-DOTA-Trasztusumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2+ breast cancer
- Development of 64Cu-NOTA-Trastuzumab for HER2 Targeting: A Radiopharmaceutical with Improved Pharmacokinetics for Human Studies
- Radioiodinated Small-Molecule Tyrosine Kinase Inhibitor for HER2-Selective SPECT Imaging
- Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma
- Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer
- Diagnostic PET Imaging of Mammary Microcalcifications Using 64Cu-DOTA-Alendronate in a Rat Model of Breast Cancer
- Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer
- Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers
- Decoding Intratumoral Heterogeneity of Breast Cancer by Multiparametric In Vivo Imaging: A Translational Study
- Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET
- ImmunoPET/MR imaging allows specific detection of Aspergillus fumigatus lung infection in vivo
- Molecular Imaging of Biomarkers in Breast Cancer
- Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2
- Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
- Imaging-Based Treatment Adaptation in Radiation Oncology
- Signatures of post-zygotic structural genetic aberrations in the cells of histologically normal breast tissue that can predispose to sporadic breast cancer